Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 251 to 275 of 335

Guidance and quality standards awaiting development
TitleType
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433Technology appraisal guidance
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawalQuality standard
Safeguarding adults in care homesQuality standard
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]Technology appraisal guidance
Secondary care management of malignant hypertensionQuality standard
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionalsQuality standard
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147Technology appraisal guidance
Sleep disordered breathingQuality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needsQuality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Technology appraisal guidance
Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesionsMedical technologies guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All